Skip to content
by Legal Desire
13 August 2024

Latham & Watkins Advises scPharmaceuticals on Growth Financings

Advising firms

Deal team

14 lawyers named
LawyerFirmSeniorityPracticeOffice
Haim Zaltzman Lead Latham & Watkins LLP Partner Not stated Not stated
Dan Van Fleet Lead Latham & Watkins LLP Partner Not stated Not stated
Erin Cusenbary Latham & Watkins LLP Associate Not stated Not stated
Tony Noh Latham & Watkins LLP Associate Not stated Not stated
Ian Drazen Latham & Watkins LLP Associate Not stated Not stated
Kirt Switzer Latham & Watkins LLP Partner tax Not stated
Gregory Conyers Latham & Watkins LLP Associate tax Not stated
Jekkie Kim Latham & Watkins LLP Partner healthcare and life sciences Not stated
Mizuna Sekine Latham & Watkins LLP Associate healthcare and life sciences Not stated
Patrick Chew Latham & Watkins LLP Associate healthcare and life sciences Not stated
Betty Pang Latham & Watkins LLP Partner FDA regulatory Not stated
Chad Jennings Latham & Watkins LLP Counsel FDA regulatory Not stated
Josh Friedman Latham & Watkins LLP Partner ERISA Not stated
Wesley Holmes Latham & Watkins LLP Partner corporate Not stated

Stated terms

Stated value
USD 125m (US$125 million)
What the figure measures
Facility amount
Client
scPharmaceuticals Inc.Borrower
Counterparties
Perceptive Advisors (Lenders)